AMIX

Autonomix Medical
AMIX

$0.7913

4.12%

Market Cap: $18.2M

About: Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Employees: 8

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

60% more funds holding

Funds holding: 10 [Q1] → 16 (+6) [Q2]

0.3% more ownership

Funds ownership: 0.18% [Q1] → 0.47% (+0.3%) [Q2]

11% less capital invested

Capital invested by funds: $100K [Q1] → $88.9K (-$11.1K) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$1.40

77%

upside

Avg. target

$1.40

77%

upside

High target

$1.40

77%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Ladenburg Thalmann

77%upside

$1.40

Buy

Initiated

3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

THE WOODLANDS, TX, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix will present at the H.C. Wainwright 26 th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY.

Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment Conference

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress

Presentation to discuss latest developments in future AI applications in interventional radiology, specifically highlighting the early results from the Company's ongoing proof-of-concept (PoC) human clinical trial

Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2024 CIRSE Annual Congress

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company's website . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company's recently completed transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator.

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, July 24 th at 4:00 PM ET THE WOODLANDS, TX, July 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, July 24, 2024 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook.

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Brad Hauser, Chief Executive Officer of Autonomix, discusses the Company's agreement to license FDA-cleared ablation technology from RF Innovations, Inc.

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Covering Technology License Agreement

Why Is Autonomix Medical (AMIX) Stock Down 17% Today?

Autonomix Medical (NASDAQ: AMIX ) stock is taking a beating on Tuesday after the development stage medical device company saw its shares undergo a rally yesterday. That came as it provided updates on its pancreatic cancer pain management device.

Why Is Autonomix Medical (AMIX) Stock Down 17% Today?

Why Is Autonomix Medical (AMIX) Stock Up 120% Today?

Medical device firm Autonomix Medical (NASDAQ: AMIX ) popped into traders' radar on Monday, peaking at 150% before engaging in choppy trading. An announcement of a licensing agreement with RF Innovations, a privately held medical technology specialist, catapulted sentiment.

Why Is Autonomix Medical (AMIX) Stock Up 120% Today?

Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company's ongoing human clinical trial

Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer.

Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

See News Rankings